Lantheus Holdings, Inc. LNTH

Company Overview

Lantheus Holdings, Inc. is a U.S.-based radiopharmaceutical company focused on diagnostic imaging agents, targeted radiotherapeutics, and artificial intelligence-enabled imaging solutions. The company operates primarily in the healthcare, nuclear medicine, and precision oncology industries, developing products used by hospitals, imaging centers, and physician practices for disease detection, characterization, and treatment planning. Its core revenue drivers include radiodiagnostic products used in cardiology and oncology imaging, most notably the positron emission tomography (PET) imaging agent PYLARIFY for prostate cancer imaging and DEFINITY for ultrasound enhancement. Lantheus also generates revenue through strategic collaborations, licensing arrangements, and manufacturing services related to radiopharmaceutical technologies.

Founded in 1956 as part of New England Nuclear and later operating under Bristol-Myers Squibb before becoming an independent company, Lantheus evolved from a traditional diagnostic imaging supplier into a precision medicine and radiopharmaceutical platform company. The company has increasingly emphasized oncology-focused imaging and theranostics, leveraging its manufacturing and distribution infrastructure in nuclear medicine. Its strategic positioning is supported by an established commercial network in radiopharmaceutical distribution, specialized production capabilities, and relationships with imaging providers across the United States and selected international markets.

Business Operations

Lantheus organizes its operations around diagnostic imaging products, radiopharmaceutical commercialization, and precision diagnostics platforms. The company’s principal business units include PYLARIFY, DEFINITY, and precision diagnostics initiatives associated with oncology imaging and radiotherapeutics. Revenue is primarily generated through product sales, particularly from prostate cancer imaging agents, contrast imaging agents, and related radiopharmaceutical services. The company maintains domestic operations across the United States while also serving customers in selected international markets through distribution partnerships and regional commercialization arrangements.

The company controls specialized radiopharmaceutical manufacturing, supply chain logistics, and isotope handling infrastructure that are critical to time-sensitive nuclear medicine products. Lantheus has also expanded through partnerships and acquisitions involving targeted oncology and theranostic technologies. Significant relationships have included collaborations tied to prostate-specific membrane antigen (PSMA) imaging and radiotherapeutic development. Subsidiaries and acquired platforms have supported the expansion of imaging biomarkers, AI-enabled diagnostic tools, and next-generation radiopharmaceutical assets.

Strategic Position & Investments

Lantheus has strategically prioritized precision oncology, radiotheranostics, and molecular imaging as its primary growth areas. The company has invested heavily in expanding the commercial reach of PYLARIFY and building a broader oncology portfolio through acquisitions, licensing agreements, and pipeline investments. Major strategic transactions have included the acquisition of Cerveau Technologies and investments related to radiotherapeutic development platforms. The company has also pursued opportunities involving alpha- and beta-emitting isotopes used in targeted cancer therapies.

In addition to internal research and commercialization efforts, Lantheus has expanded its portfolio through minority investments and partnerships in emerging diagnostic and therapeutic technologies. The company has shown particular interest in PSMA-targeted imaging, Alzheimer’s disease diagnostics, and theranostic oncology applications. Public filings and investor materials indicate a long-term strategy centered on combining imaging diagnostics with therapeutic applications to support personalized medicine and precision treatment pathways.

Geographic Footprint

Lantheus is headquartered in Bedford, Massachusetts, with operational infrastructure concentrated in the United States. The company’s largest commercial presence remains in North America, where it maintains distribution, manufacturing, and radiopharmaceutical logistics capabilities supporting hospitals, imaging centers, and oncology providers. Its products are distributed across major U.S. healthcare markets through direct sales channels and specialized nuclear medicine networks.

Internationally, Lantheus maintains commercial relationships and distribution arrangements in parts of Europe, Canada, and selected global markets through licensing and partnership structures. While the company’s revenue base is primarily U.S.-focused, its radiopharmaceutical technologies and intellectual property have broader international relevance, particularly in oncology imaging and precision diagnostics. Its operational influence is strengthened by participation in global radiopharmaceutical supply chains and isotope sourcing arrangements.

Leadership & Governance

Lantheus leadership has emphasized disciplined capital allocation, oncology-focused expansion, and the integration of diagnostics with targeted therapeutics. Corporate governance is overseen by a board of directors and executive leadership team with experience in pharmaceuticals, medical imaging, biotechnology, and healthcare operations. Public company disclosures and executive commentary have consistently highlighted innovation in precision medicine, commercial scalability, and strategic acquisitions as central elements of the company’s direction.

Key executives include:

• Brian Markison – Chairman of the Board
• Brian A. Jacobsen – Chief Executive Officer
• Robert J. Marshall – Chief Financial Officer
• Mary Anne Heino – Former President and Chief Executive Officer
• Paul Blanchfield – Chief Legal Officer and Corporate Secretary
• Samir Panchal – Chief Business Officer
• Amanda Cook – Chief Human Resources Officer

The company’s leadership strategy has focused on expanding radiopharmaceutical manufacturing capabilities, strengthening oncology commercialization, and pursuing high-growth precision imaging opportunities supported by regulatory approvals and clinical adoption trends.